Clazakizumab
As of the edition of 20 October 2026, Clazakizumab is an antibody: in active development; acts on IL6.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Antibody
- Registered trials
- 17, 4 stopped early
- Disease areas
- Lungs and airways; Bones, joints and muscles; Immune system; Skin and connective tissue; Infections; Pregnancy and women's health
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| IL6 | Interleukin-6 | P05231 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 16 | 9 | 3 | 4 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 17 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| CSL Behring | Lead sponsor of trials | 2008 to now |
| Eli Lilly | Lead sponsor of trials | 2026 to now |